Related Experiment Video
Updated: Aug 8, 2026
Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene
Published on: December 31, 2014
The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell
Izumi Nagatomo1, Toru Kumagai, Tadahiro Yamadori
1Department of Respiratory Medicine, Allergy, and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan.
Abstract:
A specific inhibitor of the Epidermal Growth Factor Receptor (EGFR), Gefitinib, displays significant antitumor effects against non-small cell lung cancers (NSCLC) that express EGFR with mutations in their tyrosine kinase domain. Although previous reports have already demonstrated that oncogenic transformation can be induced by some mutant EGFR forms, the precise differences between mutant and wild-type EGFR in terms of mechanisms of transformation have not been fully elucidated. We show here that a murine fibroblast cell line, NR6 becomes transformed by an expression level of the mutant EGFR form lacking E746-A750 that is far less than that needed with transfected wild-type EGFR. However, the mutant EGFR was unable to transform NR6 in a ligand-independent manner, as was seen with the wild-type EGFR. The consequent biological features after transformation, including DNA synthesis or cell cycle progression and biochemical characteristics such as MAPK activation mediated by the mutant EGFR are comparable and equivalent to those mediated by wild-type EGFR. These data suggest that the mutant EGFR possesses greater ligand-dependent transformation when compared with wild-type EGFR, although the exact mechanisms to account for this characteristic remain to be defined.
Insights
Mutant Epidermal Growth Factor Receptor (EGFR) transforms cells more effectively than wild-type EGFR, but requires ligand activation. This suggests enhanced ligand-dependent transformation mechanisms for mutant EGFR in non-small cell lung cancer.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Gefitinib, an Epidermal Growth Factor Receptor (EGFR) inhibitor, shows efficacy against EGFR-mutated non-small cell lung cancer (NSCLC).
- Mechanisms underlying oncogenic transformation by mutant EGFR forms compared to wild-type EGFR are not fully understood.
Purpose of the Study:
- To investigate the transformation potential of a specific mutant EGFR (lacking E746-A750) compared to wild-type EGFR.
- To elucidate differences in transformation mechanisms, including ligand dependency and downstream signaling.
Main Methods:
- Transfection of NR6 murine fibroblast cells with mutant and wild-type EGFR constructs.
- Assessment of cell transformation, DNA synthesis, cell cycle progression, and MAPK activation.
- Evaluation of ligand-dependent and ligand-independent transformation.
Main Results:
- Mutant EGFR (lacking E746-A750) transformed NR6 cells at a lower expression level than wild-type EGFR.
- Mutant EGFR-mediated transformation was ligand-dependent, unlike wild-type EGFR.
- Biological and biochemical characteristics, including MAPK activation, were comparable between mutant and wild-type EGFR-transformed cells.
Conclusions:
- Mutant EGFR exhibits enhanced ligand-dependent transformation compared to wild-type EGFR.
- The precise molecular mechanisms driving this enhanced transformation require further investigation.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
